NFKB1 and prostate neoplasm: In conclusion, we have shown that DEX attenuates docetaxel-induced AP-1 and NF-κB activation, reducing the synthesis of proangiogenic factors in both CaP and endothelial cells, with an ultimate effect of reducing de novo vessel development in a prostate tumour.